Alshahrani Mohammed S, Aldandan Hassan W
Department of emergency and critical care medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Alkhobar, Saudi Arabia.
Department of Critical Care Medicine, King Fahad Hospital of the University, Alkhobar, Saudi Arabia.
Int J Emerg Med. 2021 Apr 13;14(1):21. doi: 10.1186/s12245-021-00344-x.
Out-of-hospital cardiac arrest (OHCA) is a common cause of death worldwide (Neumar et al., Circulation 122:S729-S767, 2010), affecting about 300,000 persons in the USA on an annual basis; 92% of them die (Roger et al., Circulation 123:e18-e209, 2011). The existing evidence about the use of sodium bicarbonate (SB) for the treatment of cardiac arrest is controversial. We performed this study to summarize the evidence about the use of SB in patients with out-of-hospital cardiac arrest (OHCA).
We searched PubMed, Scopus, EBSCO, Web of Science, and Cochrane Library, until June 2019, for randomized controlled trials (RCTs) and observational studies that used SB in patients with OHCA. Outcomes of interest were the rate of survival to discharge, return of spontaneous circulation (ROSC), sustained ROSC, and good neurological outcomes at discharge. Odds ratio (OR) with their 95% confidence interval (CI) were pooled in a random or fixed meta-analysis model.
A total of 14 studies (four RCTs and 10 observational studies) enrolling 28,412 patients were included; of them, eight studies were included in the meta-analysis. The overall pooled estimate did not favor SB or control in terms of survival rate at discharge (OR= 0.66, 95% CI [0.18, 2.44], p=0.53) and ROSC rate (OR= 1.54, 95% CI [0.38, 6.27], p=0.54), while the pooled estimate of two studies showed that SB was associated with less sustained ROSC (OR= 0.27, 95% CI [0.07, 0.98], p=0.045) and good neurological outcomes at discharge (OR= 0.12, 95% CI [0.09, 0.15], p<0.01).
The current evidence demonstrated that SB was not superior to the control group in terms of survival to discharge and return of spontaneous circulation. Further, SB was associated with lower rates of sustained ROSC and good neurological outcomes.
院外心脏骤停(OHCA)是全球常见的死亡原因(Neumar等人,《循环》122:S729 - S767,2010年),在美国每年约有30万人受其影响;其中92%的人死亡(Roger等人,《循环》123:e18 - e209,2011年)。关于使用碳酸氢钠(SB)治疗心脏骤停的现有证据存在争议。我们开展这项研究以总结院外心脏骤停(OHCA)患者使用SB的相关证据。
我们检索了PubMed、Scopus、EBSCO、科学网和考克兰图书馆,检索截至2019年6月,查找在院外心脏骤停(OHCA)患者中使用SB的随机对照试验(RCT)和观察性研究。感兴趣的结局包括出院生存率、自主循环恢复(ROSC)、持续性自主循环恢复以及出院时良好的神经功能结局。比值比(OR)及其95%置信区间(CI)采用随机或固定效应荟萃分析模型进行汇总。
共纳入14项研究(4项随机对照试验和10项观察性研究),涉及28412例患者;其中8项研究纳入荟萃分析。在出院生存率(OR = 0.66,95% CI [0.18, 2.44],p = 0.53)和自主循环恢复率(OR = 1.54,95% CI [0.38, 6.27],p = 0.54)方面,总体汇总估计不支持使用SB或对照组,而两项研究的汇总估计显示,SB与持续性自主循环恢复较少(OR = 0.27,95% CI [0.07, 0.98],p = 0.045)以及出院时良好的神经功能结局(OR = 0.12,95% CI [0.09, 0.15],p < 0.01)相关。
当前证据表明,在出院生存率和自主循环恢复方面,SB并不优于对照组。此外,SB与持续性自主循环恢复率降低以及良好的神经功能结局相关。